AT-04 / Attralus - LARVOL DELTA

Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023 (GlobeNewswire) - "Attralus...today announced new preclinical data for AT-04 and AT-07, the Company’s pan-amyloid removal (PAR) therapeutic candidates targeting neurodegenerative disorders. The data was presented in an oral presentation at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases (March 28–April 1, 2023) in Gothenburg, Sweden....AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrils. AT-04 demonstrated in vivo target engagement and binding to Aβ plaques in 5xFAD mouse model. AT-04 and AT-07 demonstrated binding to Aβ plaques in brain tissue sections from patients with AD."

Preclinical • Alzheimer's Disease • CNS Disorders • Lewy Body Disease • Parkinson's Disease

DEVELOPMENT OF BRAIN SHUTTLE ENABLED AT-04, A NOVEL PEPTIBODY THAT BINDS NEUROPATHOLOGIC FIBRILLAR AGGREGATES (ADPD 2023) - "Results In contrast to an Aducanumab homolog, AT-04 bound to synthetic phosphorylated tau aggregates in addition to Aβ(1-40) synthetic fibrils. The effect of the VNAR brain shuttles fused to AT-04 on binding Aβ(1-40) fibrils, Fc-gamma receptors, phagocytic activity and colocalization with amyloid plaques in AD brain will be compared to that of AT-04 alone. Conclusions Conjugation of AT-04 to a VNAR-derived brain shuttle to enhance brain penetration has the potential to effectively clear neuropathic fibrillar deposits and offer a novel immunotherapeutic for patients with AD."

TFRC

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders (GlobeNewswire) - "Attralus, Inc...and Ossianix...announced today that they have entered into a definitive agreement using Ossianix' brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease. Under the terms of the agreement, Attralus will use the patented VNAR antibody developed by Ossianix to help deliver AT-04, its developmental pan-amyloid removal (PAR) therapeutic candidate, across the BBB to the brain....AT-04, a peptibody, is a fusion of the Company's PAR-peptide technology with the fragment crystallizable region (Fc) component of an immunoglobulin G1 (IgG1) antibody. The latest preclinical data for AT-04 demonstrate potent binding to multiple types of amyloid, as well as Aβ, tau, and α-synuclein fibrils in neurodegenerative disorders."

Licensing / partnership • Preclinical • Alzheimer's Disease • CNS Disorders